临床相关出血作为大出血替代结局的评估:随机对照试验的荟萃分析验证
该荟萃分析系统评价了新型抗凝药与标准治疗随机III期试验中临床相关出血(CRB)作为大出血替代结局的有效性。在骨科手术后预防(13项研究)、急性静脉血栓栓塞治疗(12项研究)和房颤(7项研究,22层)中,CRB与大出血的相对风险关联强度R2trial分别为0.69、0.28(双盲研究为0.68)和0.59。尽管存在表观相关性,但宽置信区间提示CRB可能不是可接受的替代结局。
要点
- 在骨科手术后预防中,大出血和CRB发生率分别为1.12%和3.56%,R2trial为0.69(95%CI 0.34-0.93)。
- 在急性VTE研究中,大出血和CRB发生率分别为1.87%和9.07%,R2trial为0.28(95%CI 0.01-0.80)。
- 在房颤研究中,大出血和CRB发生率分别为4.82%和15.3%,R2trial为0.59(95%CI 0.15-0.82)。
核心结论
- 尽管CRB与大出血在大型骨科手术、房颤和双盲急性VTE研究中存在表观相关性,但宽置信区间提示CRB可能不是任何这些设置中可接受的替代结局。
研究设计与样本
- 系统综述了比较新型抗凝药与标准治疗的随机III期试验,涵盖大型骨科手术后静脉血栓栓塞预防、静脉血栓栓塞治疗或房颤卒中和系统性栓塞预防,并报告大出血和CRB发生率。
- 通过R2trial及其95%置信区间衡量大出血与CRB相对风险之间的关联强度,评估CRB作为大出血替代结局的有效性。
主要发现
- 在术后预防设置(13项研究)中,大出血和CRB发生率分别为1.12%和3.56%,R2trial为0.69(95%CI 0.34-0.93)。
- 在急性VTE研究(n=12)中,大出血和CRB发生率分别为1.87%和9.07%;仅考虑双盲研究(n=7)时,相应R2trial值分别为0.28(95%CI 0.01-0.80)和0.68(95%CI 0.09-1.00)。
- 在房颤研究(n=7;22层)中,大出血和CRB发生率分别为4.82%和15.3%,R2trial为0.59(95%CI 0.15-0.82)。
局限性
- 宽置信区间提示CRB可能不是任何这些设置中可接受的替代结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Essentials Surrogacy of clinically relevant bleeding (CRB) for major bleeding has never been validated. Our meta-analysis evaluated CRB surrogacy in trials of new versus traditional anticoagulants. Surrogacy was not validated in orthopedic surgery, venous thromboembolism or atrial fibrillation The difficulty in demonstrating the surrogacy may reflect a lack of homogeneity in its definition SUMMARY: Background Clinically relevant bleeding (CRB), comprising major bleeding and clinically relevant non-major bleeding, has been used as a surrogate for major bleeding in most anticoagulant trials. The validity of this surrogate to estimate trade-off between thrombotic and bleeding events in clinical trials was never assessed. Methods We systematically reviewed randomized phase III trials comparing new anticoagulants with the standard of care for venous thromboembolism prevention following major orthopedic surgery, venous thromboembolism (VTE) treatment, or stroke and systemic embolism prevention in atrial fibrillation (AF), and reporting both major bleeding and CRB rates. The validity of CRB as a surrogate for major bleeding was assessed according to the strength of the association between the relative risks of major bleeding and CRB, measured by the use of R2trial and its 95% confidence interval (CI). Results In the postoperative prophylactic setting (13 studies), major bleeding and CRB rates were 1.12% and 3.56%, respectively, and R2trial was 0.69 (95% CI 0.34-0.93). For acute VTE studies (n = 12), major bleeding and CRB rates were 1.87% and 9.07%; the corresponding R2trial values were 0.28 (95% CI 0.01-0.80) and 0.68 (95% CI 0.09-1.00) when only double-blind studies were considered (n = 7). For AF studies (n = 7; 22 strata), major bleeding and CRB rates were 4.82% and 15.3%, and R2trial was 0.59 (95% CI 0.15-0.82). Conclusion Despite an apparent correlation between CRB and major bleeding in major orthopedic surgery, AF, and double-blind acute VTE studies, the wide CIs suggest that CRB might not be an acceptable surrogate outcome in any of these settings.
引用
- Laporte S, Chapelle C, Bertoletti L, et al. Assessment of clinically relevant bleeding as a surrogate outcome for major bleeding: validation by meta-analysis of randomized controlled trials. J Thromb Haemost. 2017. PMID: 28544422. doi:10.1111/jth.13740
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。